Your browser doesn't support javascript.
loading
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Hezel, A F; Noel, M S; Allen, J N; Abrams, T A; Yurgelun, M; Faris, J E; Goyal, L; Clark, J W; Blaszkowsky, L S; Murphy, J E; Zheng, H; Khorana, A A; Connolly, G C; Hyrien, O; Baran, A; Herr, M; Ng, K; Sheehan, S; Harris, D J; Regan, E; Borger, D R; Iafrate, A J; Fuchs, C; Ryan, D P; Zhu, A X.
Afiliación
  • Hezel AF; Division of Hematology/Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
  • Noel MS; Division of Hematology/Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
  • Allen JN; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Abrams TA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Yurgelun M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Faris JE; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Goyal L; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Clark JW; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Blaszkowsky LS; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Murphy JE; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Zheng H; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
  • Khorana AA; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Connolly GC; Division of Hematology/Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
  • Hyrien O; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
  • Baran A; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
  • Herr M; Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.
  • Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sheehan S; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Harris DJ; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Regan E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Borger DR; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Fuchs C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ryan DP; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Zhu AX; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Br J Cancer ; 111(3): 430-6, 2014 Jul 29.
Article en En | MEDLINE | ID: mdl-24960403
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Vesícula Biliar Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Vesícula Biliar Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos